Fig. 7), which further confirms that PTEN status and/or PI3K pathway alteration may be one of the determinants for the synergism between biguanide and erlotinib combination, and such synergism can be applied to cancer types other than breast cancer. This evidence concerns the gene PTEN and cancer.